Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-20RB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-20RB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Expressed in HEK293 for native glycosylation. |
View IL20RB Products |
| Gene Delivery | IL-20RB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View IL20RB Products |
| Benchmark Ab | Anti-IL-20RB Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View IL20RB Products |
| Validator | IL-20RB siRNA Set For target knockdown validation in primary cells or cell lines. |
View IL20RB Products |
| Related Target A | IL-20RA Required heterodimerization partner for IL-19, IL-20, and IL-24 signaling complexes. |
View IL20RA Products |
| Related Target B | IL-22RA1 Alternative heterodimerization partner forming the functional IL-20R2/IL-22R1 receptor complex. |
View IL22RA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with strictly verified sequences and >95% purity. |
| Heterodimerization interface blocking assays | Co-expressed or highly stable monomeric ECD-Fc proteins designed to preserve native conformation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown and specificity verification. |
Live IL-20RB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-20RB therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and tissue-targeted delivery systems. As first-generation therapies targeting the IL-20 pathway reach the clinic, the next wave of R&D is targeting the specific blockade of IL-20RB to simultaneously inhibit IL-19, IL-20, and IL-24 signaling, offering a broader and more effective anti-inflammatory profile in skin and joint diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | AbbVie, Merck | Psoriasis, Atopic Dermatitis | Ligand-blocking assays (Need high-purity, sequence-verified ECD-Fc) |
| Bispecific Antibody | Innovative Biotechs | Rheumatoid Arthritis, IBD | Heterodimer validation (Need both IL-20RB and IL-20RA/IL-22RA1 proteins) |
| Lentiviral Cell Engineering | Academic Research, CROs | Autoimmune Screening | Stable expression verification (Need high-titer Lentivirus for stable cell lines) |